Klinikum Coburg GmbH

The medical center is at the forefront of cardiovascular interventions, focusing on innovative treatments for complex heart conditions. The EPIDAURUS trial exemplifies this by exploring advanced antiplatelet therapy strategies to mitigate ischemic events in patients with atrial fibrillation and acute coronary syndromes undergoing percutaneous coronary intervention (PCI).

• Advanced Antiplatelet Therapy
• Acute Coronary Syndromes
• Percutaneous Coronary Intervention (PCI)

Through rigorous research, the center aims to enhance patient outcomes by reducing the risk of ischemic complications while managing bleeding risks effectively.

Specializing in hypertension management, the center conducts pivotal studies like the TARGET BP I trial, which evaluates the efficacy of renal denervation using alcohol-mediated neurolysis. This approach is designed to improve blood pressure control in patients with uncontrolled hypertension, offering a novel adjunct to traditional antihypertensive medications.

• Renal Denervation Techniques
• Alcohol-Mediated Neurolysis
• Combination Antihypertensive Therapy

The center's research contributes significantly to the development of cutting-edge therapies that aim to provide better management of hypertension, potentially reducing the burden of cardiovascular diseases.

Focusing on stroke prevention in patients with atrial fibrillation, the center's research includes the Optimal Anticoagulation trial. This study investigates the long-term benefits of oral anticoagulation compared to antiplatelet therapy alone in reducing cerebral embolic events post-catheter ablation.

• Long-term Oral Anticoagulation
• Catheter Ablation Outcomes
• Cerebral Embolic Event Reduction

By advancing knowledge in anticoagulation strategies, the center aims to improve the quality of life and reduce stroke risk in patients with atrial fibrillation.